Northwell Health Named One of the World’s Most Ethical Companies for 2024

Northwell Health

Northwell Health was named one of World’s Most Ethical Companies for 2024 by Ethisphere, one of only four healthcare providers in the world to be recognized. It is the ninth time Northwell has been named to the list, joining 136 companies from 20 countries and 44 industries in being honored.

Ethisphere

Ethisphere, which announced the list today, is a global leader in defining and advancing the standards of ethical business practices. Northwell Health was recognized because of its culture, practices, and compassionate care, and for treating some of the most diverse communities in the world.

Michael Dowling, president and CEO of Northwell

“Acting ethically is at the heart of everything we do at Northwell Health, and it’s an honor to be recognized by Ethisphere as one of the World’s Most Ethical Companies. Northwell is proud to stand shoulder-to-shoulder with global leaders in ethical business practices, and showing the profound impact ethical decision-making has on patient outcomes and community trust.”

The World’s Most Ethical Companies assessment is grounded in Ethisphere’s proprietary Ethics Quotient®, an extensive questionnaire that requires companies to provide over 240 different proof points on their culture of ethics; environmental, social, and governance (ESG) practices; ethics and compliance program; diversity, equity and inclusion; and initiatives that support a strong value chain. That data undergoes further qualitative analysis by Ethisphere’s panel of experts who spend thousands of hours vetting and evaluating each year’s group of applicants.

Greg Radinsky, Northwell senior vice president and chief corporate compliance officer

“This recognition highlights Northwell’s ongoing efforts to foster a culture of integrity, respect and trust, reflecting our belief that ethical leadership is fundamental to sustainable success. We are committed to continuing on the path of integrity, ingenuity and excellence that drives everything we do.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version